To explore the experience of adults living with hepatitis C in a new era of interferon-free treatment.
| INTRODUCTION
The hepatitis C virus (HCV) is a leading cause of mortality and morbidity worldwide, posing a major challenge to global public health (World Health Assembly, 2016) . The virus is acquired through exposure to infected blood, and whilst the spontaneous resolution of acute infection is possible, long-term infection occurs in approximately 60%-85% of cases. Chronic HCV is characterised by slowly progressing liver fibrosis, which leads to the development of cirrhosis in approximately 10%-20% of patients (Westbrook & Dusheiko, 2014) . Injecting drug use is the cause of a substantial proportion of the global burden of HCV disease, with injecting drug use-attributable HCV highest in high-income nations (Degenhardt et al., 2016) .
Within the UK, the most recent national estimates suggest around 214,000 individuals are infected, of which approximately 37,000 reside in Scotland (Public Health England, 2015) .
| Background
For over 15 years, recurrent qualitative investigation has illuminated how HCV is experienced, understood and constructed by those living with the virus. Studies commonly portray a disruptive and distressing phenomenon manifest in social, emotional and physical spheres of illness, with specific facets of experience such as diagnosis (Glacken, Kernohan, & Coates, 2001) , fatigue (Glacken, Coates, Kernohan, & Hegarty, 2003; Zalai, Carney, Sherman, Shapiro, & McShane, 2016) and stigma (Butt, Paterson, & McGuinness, 2008; Fraser & Treloar, 2006) often emphasised. This body of work provides insight into how HCV is conceptualised by those it affects, exposing common expectations of chronic morbidity and altered life trajectories (Conrad, Garrett, Cooksley, Dunne, & MacDonald, 2006; Paterson, Butt, McGuinness, & Moffat, 2006; Sutton & Treloar, 2007) . In contrast, the normalisation of HCV has also been reported from studies focused on people who inject drugs (PWID), revealing constructions of HCV infection as inevitable, unavoidable and ultimately part of the PWID identity (Harris, 2009; Roy, Nonn, Haley, & Cox, 2007; Wozniak, Prakash, Taylor, & Wild, 2007) . Importantly, these insights into lived experience are situated within their sociocultural and temporal contexts, and have been repeatedly entwined with societal understandings of the challenging treatment available for HCV at the time and an associated expectation of not being cured (Fraenkel, McGraw, Wongcharatrawee, & Garcia-Tsao, 2005; Groessl et al., 2008; Hill, Pfeil, Moore, & Richardson, 2015; North, Devereaux, Pollio, Hong, & Jain, 2014; Swan et al., 2010) .
Historically, the treatment of HCV was stubbornly reliant on the notoriously unpleasant immunomodulating agent interferon-a. This drug, when combined with the nucleoside analogue ribavirin, comprised the dual therapy standard of care for HCV which endured throughout the 2000s and into the early part of this decade. These drugs needed to be taken for up to 48 weeks, demonstrated limited efficacy and came with an extensive catalogue of both physical and neuropsychiatric side effects (Manns, Wedemeyer, & Cornberg, 2006) . Multiple studies exploring the experience of taking interferon-based regimens have repeatedly emphasised the severity of the treatment and the apprehension and fear it could produce (Hopwood & Treloar, 2005; Kinder, 2009; Sheppard & Hubbert, 2006) . The arduous and protracted nature of HCV treatment contributed towards the low rates of uptake recurrently reported (Grebely et al., 2009; Lazarus, Sperle, Maticic, & Wiessing, 2014; Midgard, Bramness, Skurtveit, Haukeland, & Dalgard, 2016) , although multiple patient, provider and social factors have been identified as barriers to individuals accessing and completing a period of interferon-based therapy McGowan & Fried, 2012) . These barriers included poor adherence (and provider concerns of poor adherence), comorbidities (most notably psychiatric disorders), perceived and actual risks of reinfection and societal stigma (Grebely, Oser, Taylor, & Dore, 2013; McGowan & Fried, 2012) and were most acutely felt among groups of PWID. The bulk of literature focused on the lived experience of HCV is predominantly situated within the context of this demanding, traumatic and inadequate treatment.
Whilst the use of interferon-based dual therapy persists in many regions of the world, recent pharmacological advances have given some individuals, in mostly high-income nations, the potential to access new drugs that offer a highly effective and well-tolerated cure. These interferon-free direct-acting antiviral (DAA) regimens offer substantially shorter treatment durations, improved side-effect profiles and have demonstrated sustained virological response rates of over 90% (Asselah, Boyer, Saadoun, Martinot-Peignoux, & Marcellin, 2016) . The dawn of this new era of HCV therapy has been heralded as a medical triumph (Chung & Baumert, 2014) , although the global use of interferon-free DAAs has been hampered by their considerable costs. How such remarkable and rapid advances in the HCV treatment landscape may be influencing the experience of being HCV positive has so far received little attention. To date, only three articles focused on the lived experience of HCV have used qualitative data collected during the interferon-free DAA era. One of these articles focused exclusively on the Aboriginal community in Australia (Treloar et al., 2016) , one on the experience of taking interferon-free treatment (Whiteley, Whittaker, Elliott, & Cunningham-Burley, 2016 ) and the other was limited to an examination of What does this paper contribute to the wider global community?
• This paper provides the first exploration of how individuals living with hepatitis C are experiencing an interferonfree era of therapy.
• The arrival of interferon-free treatments in clinical practice has yet to challenge societal constructions and understandings of hepatitis C.
• The emergence of treatment rationing provides fresh challenges for engaging disenfranchised hepatitis C populations in care.
HCV-related fatigue (Zalai et al., 2016) . A broader contemporary understanding of how HCV is being experienced and perceived is therefore currently absent.
In Scotland, during the timeframe of this study, a number of interferon-free DAA regimens were granted approval for use in clinical practice. Access to these medications was restricted due to budgetary constraints, resulting in guidelines recommending concurrent provision of both interferon-free (typically a 12 week course of treatment) and interferon-based (up to 48 weeks of treatment) therapies to those accessing care (Healthcare Improvement Scotland and NHS National Services Scotland, 2015) . Treatment rationing was dependent on a number of factors, including HCV genotype and the degree of liver disease. Participants in the study recruited from specialist HCV care had been made aware of the treatments available and associated restrictions as part of routine care by their regular healthcare providers. This study aims to recontextualise the lived experience of HCV within the context of this new therapeutic era.
In doing so, it seeks to consider the influence of an advancing therapeutic landscape on constructions of the illness.
| ME TH ODS

| Design
A social phenomenological perspective underpins the study. This sociological approach rotates phenomenology outwards and postulates that the way humans construct their perspective on the outside world is not a purely individual process. It emphasises the importance of the social world in establishing the meaning of phenomena, asserting the intersubjective world as the foundation for human knowledge and experience (Shaw & Connelly, 2012) . Social phenomenological research explores the shared features of subjective experience that define a phenomenon's meaning, focusing on the commonalities found in the life-worlds of more than one actor (Ajiboye, 2012).
The qualitative study design comprised of face-to-face, semistructured interviews. In total, 20 participants with HCV were purposefully sampled from two locations: a hospital-based infectious diseases outpatient clinic, and a primary care doctors' surgery, both situated within a large Scottish city. The use of two recruitment sites aimed to select participants who had both engaged, and not engaged, with HCV specialist care. Further characteristics of the purposive sample were identified to recruit a diverse group of participants, theorising that patterns emerging from great variation are of particular interest in capturing the shared dimensions of a phenomenon (Patton, 2015) . These characteristics were date of diagnosis, mode of acquisition, HCV treatment history and degree of liver disease, in addition to various socio-demographic factors. The identification of these characteristics was based on a literature review conducted in the process of developing the study and reflection by the research team on what may constitute "common sense" categories (Mason, 2002) . The sample size of 20 was deemed sufficient to capture this range of diverse characteristics, but not so large that detailed and nuanced analysis of the data would be compromised (Mason, 2002) .
Inclusion criteria consisted of being diagnosed with HCV for more than 6 months, aged 16 years or over and able to converse in English. The requirements of the maximum variation sample were also taken into account as recruitment progressed. Individuals who fulfilled the criteria were approached by their healthcare provider, and consent was obtained for their details to be passed to the researcher (DW) if interest was shown in participating. Records were not kept of how many individuals were approached but declined to participate. A meeting was then arranged with the researcher, where the purpose of the study was explained, any questions answered and written informed consent obtained. The interviews were audio-recorded using an encrypted recording device and transcribed verbatim by DW, during which any information that may identify the participant was obscured from the narrative. Following each interview, a reflective account was written and added to field notes in a research diary. Each participant was offered a £15 supermarket voucher in line with national guidelines, although three participants declined payment for their involvement in the study.
| Data collection
| Analysis
Six phases of thematic analysis were used to guide the analytical process (Braun & Clarke, 2006) . Each transcript was read repeatedly by two researchers (DW and AW) to ensure subsequent coding and theme development remained grounded in the participants' narratives. Inductive coding was then conducted by DW using NVivo v.10 software to help manage the data. Whilst depicted as a linear process, the interviewing, transcribing and coding of the narratives occurred in parallel, with each activity informing the others. This analytical process began following the initial interview, and as this iterative process continued, groups of codes were gradually combined, resulting in the formation of a number of subthemes. This cycle of analysis aided the
identification of data saturation; coding of the final three transcripts aligned with the provisional subthemes already developed.
These subthemes were then combined into candidate themes, which were examined in relation to the corpus of data and the research diary. During the analytical process, all four authors met regularly to probe and interrogate the evolving analysis, and to contest any preconceptions DW may have brought to the study due to his work history and association with the topic, consistent with the concept of bracketing. Within social phenomenological research, bracketing demands that belief in the existence of the world as we know it is suspended, and encourages doubt that the world could be anything other than it appears (Sch€ utz, 1967) . This ongoing peer review of the analysis aided rigour and ensured the resulting themes were founded in the subjective life-worlds of the participants.
| Ethical approval
The study was considered and approved by the South East Scotland
NHS Research Ethics Committee 01 (15/SS/0010) and by Edinburgh
Napier University Research Integrity Committee.
| RESULTS
| Participants' characteristics
The characteristics of the sample are shown in Table 1 . The partici- 
| Positioning hepatitis C
The first theme illustrates how hepatitis C was understood within wider sociocultural, medical and politico-economic contexts. Participants described reactions to their medical diagnosis of HCV that positioned it within the context of their lives at the time. For example, for those who situated their diagnosis within a period of drug use, familiar reactions of shock, fear and anguish appeared mitigated by a perception that they had put themselves at risk: 
| Beyond a physical burden
The second theme reveals how the participants firmly located the emotional burden of a somatic disease as their predominant concern.
The physical aspect of HCV infection was absent from almost half of the participants' testimonies, and where it did occur, the discourse of physical disruption was rarely emphasised as particularly significant. Reduced energy and general fatigue were mentioned anecdotally, and framed by most as a manageable and slight inconvenience, rather than a life-changing condition: 
(Female, diagnosed 2008, non-cirrhotic)
Whilst the physical burden of HCV formed a weak and insubstantial pattern within the data, the impact on participants' emotional well-being was richly constructed and comprised multiple strands. (Female, diagnosed 1991, cirrhotic) Whilst this may imply that the stigma felt by participants was disproportionate to the level of stigma found within society, the narratives also alluded to the passive and covert nature of much stigma- The emphasis on the emotional burden of HCV within the narratives produced a discourse that also highlighted the importance participants placed on support. Whilst family and friends were commonly positioned as central to preserving emotional welfare, speaking to someone "outside the family," who had personal experience of living with HCV was particularly valued:
. (Female, diagnosed 2009, non-cirrhotic) 
| A new uncertainty
The final theme explores how uncertainty was etched throughout the collected narratives and the prominence of uncertainty and scepticism in understandings of new HCV therapies. The concept of uncertainty was often established during discussion of how HCV was understood at the time of diagnosis:
.
. .and [my GP] was like, can you sit down, an' I'm like I'm just in a' get my prescription, an' she was like no I need a' speak to you, an' I didn't even know what hepatitis C was, I was like, is this like HIV, is this gonna kill me? (Female, diagnosed 2012, non-cirrhotic)
Uncertainty was not limited to retrospective reflections on diagnosis but pervaded across the illness trajectory. For example, those with no history of injecting drug use repeatedly expressed uncertainty as to how HCV had been acquired, and nearly all participants voiced concerns and confusion surrounding the silent advance of liver disease:
. .you don't know how it could progress, is it changing? How fast is it progressing? Even though the appointments are six months apart what's happening inbetween? You think well, things could change an', oh,
will I know about it? (Female, diagnosed 1997, non-cirrhotic) In addition to these familiar refrains, uncertainty was also prominent in the participants' discourse surrounding HCV therapies.
Understandings of new treatment options were vague and ambiguous, with participants expressing confusion regarding the plethora of new treatment regimens becoming available:
. ' all that, all that bumf. (Male, diagnosed 1997, cirrhotic) During the study, the hospital-based recruitment site hosted two phase III randomised controlled trials (RCTs) for new HCV drugs, and an awareness of clinical trials was therefore common among the participants. However, the perception of HCV treatments as "trial drugs" was not limited to RCTs, but more commonly applied in blanket fashion to all DAAs which were available in clinic. A couple of participants who were not considering RCTs still referred to themselves as "guinea pigs," emphasising the novelty and nascent nature of the regimens. A perception persisted that despite being licensed, these drugs were still largely unknowns: (Female, diagnosed 2008, non-cirrhotic) Whilst some participants eschewed the interferon option, in favour of an uncertain wait, others embraced whatever treatment regimen was offered. This latter approach was underpinned by the protracted and challenging journeys to treatment that many participants described, and which created a sense that they had already waited long enough. A prevailing sense of wanting to be free of HCV at any cost developed for a few participants, with a willingness to accept the ordeal and disruption of interferon-based regimens: (Male, diagnosed 2000, non-cirrhotic) 
| DISCUSSION
A qualitative focus on HCV has long provided valuable insight into the experience of those living with the virus, and their understanding of the illness (e.g., Miller, McNally, Wallace, & Schlichthorst, 2012; Treloar & Rhodes, 2009 ). However, the wealth of research in this area must be viewed within its historical context, as the majority of studies were conducted during the era of arduous, and poorly efficacious, interferon-based therapy. Over the last 5 years, rapid pharmacological advances have transformed the prospects of those undergoing HCV treatment in Scotland, and whilst access to new interferon-free DAA regimens has been restricted, significantly improved therapeutic options for HCV now exist (Chung & Baumert, 2014) . This study has sought to contextualise the lived experience of HCV within this modern era of therapy, and in doing so allow exploration of whether constructions of HCV have been disturbed by the arrival of a fast, effective and tolerable cure.
The complex emotional burden of HCV was writ large throughout these contemporary narratives within familiar refrains that have dominated previous research. For example, reactions at diagnosis and the tenacity of stigma resonate with studies conducted during the interferon era (e.g., Butt et al., 2008; Conrad et al., 2006; Fraser & Treloar, 2006; Hill et al., 2015; Rhodes & Treloar, 2008) and speak to the lack of influence a rapidly improving cure has yet to exert on emotional spheres of illness. Biomedical attention on treating and curing the somatic disease has decontextualised HCV from peoples' lives, and, to date, has failed to concurrently address its wider sociocultural impact. The persistence of societal stigma continues to incite anxiety, shame and fear in those infected, perpetuating the spoiled and discreditable label of HCV (Treloar, Rance, & Backmund, 2013) , resulting in an unyielding and obstinate emotional burden of illness.
Beliefs about the illness course and duration also appeared little altered from previous studies as a discourse of chronicity wove throughout the themes. "Positioning HCV" was underpinned by an assumption that participants were at a particular point on an illness continuum and that HCV presented an advancing threat with degrees of severity and diverse trajectories. Of course, understandings of HCV as a potentially progressive disease do not automatically equate with an expectation that long-term effects would be directly experienced. Indeed, participants positioning their experience in relation to others may simply be viewed as a discursive strategy, used protectively to assess their own situation in a better light. The uncertainty with which DAA regimens were framed, however, supports a notion that voicing concerns of illness chronicity was not solely a strategic device. These effective, well-tolerated drugs, feted and lionised within medical discourse (Chung & Baumert, 2014; Pawlotsky, Feld, Zeuzem, & Hoofnagle, 2015) , were not met with the same chorus of adoration by the participants. Rather, narratives of caution, confusion and uncertainty emerged, emphasising a vague and ambiguous grasp of HCV treatment evolution. The participants' understandings and belief in this new era of therapy were too untried and untested to challenge the well-founded cultural memory of HCV as a chronic condition (Paterson et al., 2006; Sutton & Treloar, 2007) , echoing reports of a cultural lag previously described (Whiteley et al. 2016) .
A cautious framing of the effectiveness of these new medications, and beliefs surrounding the likelihood of gaining access to the drugs, also constructed an understanding that participants lacked control over their illness trajectory. An implicit acceptance of the health inequality status quo underpinned the participants' discourse, as they constructed narratives around the assumption that HCV treatment rationing was an absolute, and adapted their understanding to accommodate that assumption, rather than challenge it. This instinctive tolerance of health injustice speaks to theoretical arguments that suggest an individuals' capability to be healthy can be constrained by their physical and social environments, as well as the political, economic, cultural and legal determinants of those environments (Venkatapuram, 2011) . It resonates with the lack of entitlement and therapeutic citizenship reported within HCV communities over the years (Rhodes, Harris, & Martin, 2013; Wolfe et al., 2015) and reinforces perceptions that control over the illness lies in political and economic domains, rather than in the hands of healthcare providers or the individuals themselves.
This study has a number of limitations. The participants were a small group from one city in Scotland, and their experience was located within a particular social, cultural and political context. However, the insights gained speak to wider populations of HCV-positive individuals within high-income nations with restricted access to interferon-free DAAs. Despite recruitment attempts, the sample was also mainly composed of individuals who were already accessing specialist HCV care, who may have been more conversant with developments in HCV treatment than those who do not engage with services. The scarcity of individuals recruited from without the hospital site also contributed to the relative dearth of those who identified as current PWID.
| CONCLUSION
This exploration of the contemporary lived experience of HCV has emphasised how a rapidly improving treatment has so far failed to successfully challenge intersubjective perceptions of the illness. How long this situation may endure is unknown. Within high-income nations, the social perception of HCV may naturally evolve as the costs of interferon-free DAAs reduce, and their use proliferates.
However, in the short to medium term, understandings of HCV as a long-term, life-altering and emotionally draining illness continue to impact how individuals respond to and make sense of the infection.
The new therapeutic era of HCV may be constrained by intersubjective perceptions of the illness as a chronic, emotionally scarring condition over which there is little control.
| RELEVANCE TO CLINICAL PRACTICE
Whilst the advent of interferon-free DAA treatments has been widely eulogised, this study exposes how their arrival has yet to effectively challenge societal constructions of HCV. The perception and understanding of HCV has previously been demonstrated to adversely impact on the prevention of transmission, testing and diagnosis, engagement with care and access to treatment (Harris, Ward, & Gore, 2016; Miller et al., 2012; North et al., 2014; Sublette, Smith, George, McCaffery, & Douglas, 2015; Treloar et al., 2013) , and as these long-held and deeply 
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